Calmark Sweden AB is a privately held Swedish company founded in 2007 based on research performed at Karolinska Institutet in Stockholm. Calmark is based in Karlstad with laboratory and representation office at Greenhose Labs in Stockholm.
Torbjörn Andersson, CEO. Torbjörn has over 25 years of experience of general management, product development and sales in the life science industry. Torbjörn holds a BSc in Biochemistry, and a MBA with honors from IMD business school in Lausanne, Switzerland.
Mathias Karlsson, Medical Director, founder. The inventor of the Calmark method. Responsible for the medical development of the method and CEO of Calmark Sweden AB. Mathias is a M.D. and holds a Ph.D. at Karolinska Institutet, Sweden, within the field of perinatal asphyxia and the unique properties of specific cell damage markers that indicate the physiological status of conditions caused by an insufficient oxygen supply in tissue.
Sofia Hiort af Ornäs, CTO, founder. Co-inventor of the Calmark method and responsible for the technical product development at Calmark. Sofia has a background as a M.Sc. in chemical engineering from the Royal Institute of Technology, Sweden. She previously worked for Amersham Biosciences/GE Healthcare and SweTree Technologies, having positions as research engineer, project manager and section manager.
Ana Catarina Silva, Product Developer. Ana Catarina has a background within materials and medicinal chemistry, and holds a PhD in Organic Chemistry from University of Lisbon, Portugal. Ana Catarina has strong academic experience from applied chemistry, drug development, and method development for bioanalysis e.g. paper-based diagnostic tests for DNA/RNA.
Board of Directors
Hjalmar Didrikson, Chairman of the board since 2010. Hjalmar is co-founder of investment firm Alfvén & Didrikson. In 2010, Hjalmar left Northern Europe’s leading private equity group, EQT. He was with EQT from 2006 and managed inter alia EQT’s IPO/sale of Duni AB and public offers for Q-Med AB and HTL-Strefa SA and also served on the Boards of a handful of EQT portfolio companies. In 2004-6 he worked with one of Norway’s leading private equity funds, FSN Capital in Oslo, as an Investment Manager. In 1998-2004 he was with UBS Investment Bank in London as a Corporate Finance adviser to large European companies and investment institutions. He holds a M.Sc. from the Stockholm School of Economics with exchange studies at the MBA program of New York University, Leonard N. Stern School of Business.
Mathias Karlsson, board member since 2007. Medical Director and founder of Calmark Sweden AB. The inventor of the Calmark method. Responsible for the medical development of the method. Mathias is a M.D. and holds a Ph.D. at Karolinska Institutet, Sweden, within the field of perinatal asphyxia and the unique properties of specific cell damage markers that indicate the physiological status of conditions caused by an insufficient oxygen supply in tissue.
Peter Sjöstrand, board member since 2010. Peter is former CFO and Executive Vice President of Astra AB. Peter is a board member of Active Biotech AB, Oscar Hirsch Memory Foundation, Karolinska Development AB and School of Technology and Health (Royal Institute of Technology), Former Chairman of, inter alia, Meda AB and Gambro AB, and former board member of, inter alia, Swedish leading chain of clinics Aleris AB. Peter holds a B.Sc. from the Stockholm School of Economics and an MD from the Karolinska Institutet, Sweden.
Lars Wingefors, board member since 2014. Lars is a serial entrepreneur from Karlstad, Sweden. Founder and majority owner of Nordic Games Group (GAME, Game Outlet Europe, Nordic Games/THQ). Lars is business angel and seed investor in more than 20 startups.
Hans Risberg, board member since 2014. Hans is a shareholder from start up of the company. Hans is partner of Norges Investor lV and investing in young entrepreneurs and their companies. He has a master of science in economics and after 15 years abroad working for Gränges Metallverken, ITT and STC HR started his own investment company. Founding partner in Ledstiernan, RnB and many other young companies.
Lars-Olov Hansson, board member since 2014. Lars-Olov has worked as clinical chemist at 5 of the university hospitals in Sweden (Linköping, Malmö, Danderyd, Karolinska and Uppsala) of these 12 years was at Karolinska Hospital, Stockholm and 4 years as laboratory director at Akademiska Laboratory, Akademiska Hospital, Uppsala. Lars-Olov has published more than 140 scientific articles, five chapters in books and actively participated in more than 50 international meetings. He is a member of the Swedish Association for Clinical Chemist, the Swedish doctors Association, the American Association for Clinical Chemistry, an associated member the IFCC committee for plasma protein (C-PP), and member of the Swedish plasma protein Quality Control program in EQUALIS. Lars-Olov is today working as a consultant in laboratory medicine in Gävleborg County and Värmlands County, and as a medical business advisor to several diagnostics companies.